Mark Lakshmanan

Mark Lakshmanan

UNVERIFIED PROFILE

Are you Mark Lakshmanan?   Register this Author

Register author
Mark Lakshmanan

Mark Lakshmanan

Publications by authors named "Mark Lakshmanan"

Are you Mark Lakshmanan?   Register this Author

11Publications

172Reads

26Profile Views

Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).

Diabetes Obes Metab 2019 Jun 29;21(6):1493-1497. Epub 2019 Mar 29.

Eli Lilly and Company, Lilly Diabetes Development, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13668DOI Listing
June 2019

GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply.

Lancet Diabetes Endocrinol 2018 10;6(10):765

Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-8587(18)30239-0DOI Listing
October 2018

Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.

Diabetes Care 2005 Jul;28(7):1555-61

Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611-3008, USA.

View Article

Download full-text PDF

Source
http://care.diabetesjournals.org/content/28/7/1555.full.pdf
Web Search
http://dx.doi.org/10.2337/diacare.28.7.1555DOI Listing
July 2005